Roches NSLC mAb outperforms chemoRoche is making up lost ground in immuno-oncology. The Swiss companys PD-L1 directed immunotherapy atezolizumab is more effective in combatting lung cancer than standard chemotherapy. more ➔
Synvina: BASF and Avantium join forcesThe new joint venture Synvina is positioned in the market for drop-in bioplastics with advanced product characteristics. more ➔
CPhI sheds light on future marketsWith about 38,000 attendees and 2,500 exhibitors, CPhI worldwide in Barcelona has broken another record. Personalised 3D printed pills and hypothesis generation using big data were only two trends … more ➔
EC delays bioeconomy strategy reviewThe fate of the bioeconomy in Europe remains undecided. The evaluation of the European Commissions bioeconomy strategy plus action plan has been delayed. more ➔
Apeiron licences neuroblastoma antibodyAustrian Apeiron Biologics has outlicensed the global marketing rights for its neuroblastoma antibody dinutuximab beta to British Eusa Pharma. more ➔
Diabetes giant cuts jobsDanish insulin maker Novo Nordisk tries to relieve financial pressure by laying off 1,000 staff. The step was necessary due to challenges on the US market, the company said. more ➔
Bluebird bio selects Medigene for TCR deve... CAR T cell specialist bluebird bio has inked a potential US$1bn partnership with Medigene – to get access to the drug developers technology platform. more ➔
Update: Immunic bags €17.5mMartinsried-based autoimmune specialist Immunic AG secured financial support for the next 3.5 years from lead investors Life Sciences Partners and LifeCare Partners (LCP, Switzerland) based on prior … more ➔
iOmx hits the ground runningBacked by MPM Capital and Sofinnova, immuno-oncology specialist iOmx Therapeutics has raised €40m in its first round of financing. The German company had just been founded in spring. more ➔
BioNTech teams up with GenentechGerman immuno-oncology play BioNTech has entered into a collaboration with Roches Genentech to develop novel mRNA-based, individualised cancer vaccines. The deal will net BioNTech €278m. more ➔
